

Dethlefs Sven  
Form 4  
March 14, 2019

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Dethlefs Sven

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL  
INDUSTRIES LTD., 5 BASEL  
STREET

(Street)

PETACH TIKVA, L3 4951033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol  
TEVA PHARMACEUTICAL  
INDUSTRIES LTD [TEVA]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/12/2019

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)  
EVP Global Marketing&Portfolio

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_X\_\_\_\_ Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired (A)<br>or Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------------|-----------------------------------------|-------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------|
| Ordinary<br>Shares <sup>(1)</sup>     | 03/12/2019                              |                                                             | M                                    | 1,191                                                                   | A <sup>(2)</sup>                                                                                                   | 9,248.7                                                                 | D                                                                 |
| Ordinary<br>Shares <sup>(1)</sup>     | 03/12/2019                              |                                                             | S <sup>(3)</sup>                     | 647 <sup>(4)</sup>                                                      | D                                                                                                                  | 15.6749                                                                 | D                                                                 |
|                                       |                                         |                                                             |                                      |                                                                         | <sup>(5)</sup>                                                                                                     |                                                                         |                                                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control**

SEC 1474  
(9-02)

number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount<br>of Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Pri<br>Deriv<br>Secur<br>(Instr |                                        |
|-----------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|-------------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------|----------------------------------------|
|                                                     |                                                                       |                                         |                                                             | Code                                    | V (A) (D)                                                                                                       | Date<br>Exercisable                                            | Expiration<br>Date                                                     | Title                              | Amount<br>or<br>Number<br>of<br>Shares |
| Restricted<br>Share<br>Units                        | (2)                                                                   | 03/12/2019                              |                                                             | M                                       | 1,191                                                                                                           | (6)                                                            | (6)                                                                    | Ordinary<br>Shares (1)             | 1,191                                  |

## Reporting Owners

| Reporting Owner Name / Address                                                                            | Relationships                     |
|-----------------------------------------------------------------------------------------------------------|-----------------------------------|
|                                                                                                           | Director 10% Owner Officer Other  |
| Dethlefs Sven<br>C/O TEVA PHARMACEUTICAL INDUSTRIES<br>LTD.<br>5 BASEL STREET<br>PETACH TIKVA, L3 4951033 | EVP Global<br>Marketing&Portfolio |

## Signatures

/s/ Dov Bergwerk, as attorney-in-fact for Sven  
Dethlefs 03/14/2019

\_\_\_\_Signature of Reporting Person

\_\_\_\_Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (3) The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (4) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.6600 to \$15.6911, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security

## Edgar Filing: Dethlefs Sven - Form 4

holder of the issuer, full information regarding the number of shares sold at each separate price.

(6) Restricted share units were granted on March 12, 2015, with 1,190 vesting on March 12, 2018 and 1,191 vesting on March 12, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.